Vera Therapeutics
Coverage of Vera Therapeutics in the Nexus archive.
- STAT+: Pharmalittle: We’re reading about a Vera kidney drug approval, a U.K. Enhertu pricing deal, and more
The FDA approved Trutakna, a kidney disease drug from Vera Therapeutics, for treating IgA nephropathy at an annual price of $425,000. U.K. officials are finalizing a pricing deal with AstraZeneca and Daiichi Sankyo to provide access to Enhertu, a breast cancer drug previously deemed too costly for the U.K. market.
- Vera Therapeutics stock jumps after the FDA approved its autoimmune kidney drug
Vera Therapeutics' stock increased following FDA approval of Trutakna, a $425,000-per-year drug targeting BAFF and APRIL proteins for IgA nephropathy. The drug is the first in the U.S. to address both proteins linked to the condition.
- STAT+: FDA approves Vera Therapeutics kidney disease treatment
The FDA approved Trutakna, a new treatment for IgA nephropathy, a chronic autoimmune kidney disease, developed by Vera Therapeutics. Vera CEO Marshall Fordyce expressed excitement about bringing the drug to patients.
- STAT+: Radiopharmaceutical shows promise in post-Pluvicto setting
A radiopharmaceutical shows promise in the post-Pluvicto setting. Vera Therapeutics and the FDA agreed to accelerate analysis of a Phase 3 study for atacicept in treating IgA nephropathy, while Abivax reported positive data for an ulcerative colitis treatment despite cancer concerns.